Functional and clinical significance of thrombospondin

Platelets

Volumn 8, Issue 4, 1997, Pages 211-224

  Legrand, Chantal ^a   Dubernard, V ^a   Rabhi Sabile, S ^a   Da Silva, V Morandi ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN; THROMBOCYTE RECEPTOR; THROMBOSPONDIN;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL OCCLUSION; CANCER CELL; CELL INTERACTION; CONTROLLED STUDY; ERYTHROCYTE; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; MALARIA; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN STRUCTURE; SICKLE CELL ANEMIA; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; THROMBOCYTE MEMBRANE; THROMBOSIS; WOUND HEALING;

EID: 0030861496     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109777258     Document Type: Article

References (127)

1. Weiss HJ. Platelet physiology and abnormalities of platelet function. New Engl J Med 1975; 293: 531-41.
2. George JN, Nurden AT, Phillips DR. Molecular detects in interactions of platelets with the vessel wall. New Engl J Med 1984; 322: 1084-98.
3. Nurden AT, Caen JP. Specific roles for surface glycoproteins in platelet function. Nature 1975; 255: 720-22.
4. Murphy-Ullrich JE, Mosher DF. Localization of thrombospondin in clots formed in situ. Blood 1985; 66: 1098-104.
5. Bale MD. Noncovalent and covalent interactions of thrombospondin with polymerizing fibrin. Sem Thromb Hemos 1987; 13: 326-34.
6. Lawler J. The structural and functional properties of thrombospondin. Blood 1986; 67: 1197-209.
7. Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993; 1182: 1-14.
8. Bornstein P. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 1995; 130: 503-6.
9. Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. BioEssays 1996; 18: 71-6.
10. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996; 10: 1183-91.
11. Baenziger N, Brodle G, Majerus P. A thrombin-sensitive protein of human platelet membrane. Proc Natl Acad Sci USA 1971; 68: 240-3.
12. Lawler JW, Slayter HS, Coligan JE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 1978; 253: 8609-16.
13. Lawler J, Hynes RO. The structure of human thrombospondin. an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 1986; 103: 1635-48.
14. Lawler J, Simons ER. Cooperative binding of calcium to thrombospondin. The effect of calcium on the circular diohroism and limited tryptic digestion of thrombospondin. J Biol Chem 1983; 258: 12098-101.
15. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of Arg-Gly-Asp, calcium, and integrin receptors. J Cell Biol 1988; 107: 2351-61.
16. Sun X, Skorstengaard K, Mosher DF. Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin. J Cell Biol 1992; 118: 693-701.
17. Hogg PJ. Thrombospondin 1 as an enzyme inhibitor. Thromb Haemost 1994; 72: 787-92.
18. Clezardin P. Expression of thrombospondin by cells in culture. In: Lahav J, ed. Thrombospondin. Boca Raton. FL: CRC Press. 1993: 42-61.
19. Adams J, Lawler J. The thrombospondin family. Curr Biol 1993; 3: 188-90.
20. Bornstein P. Thrombospondins: structure and regulation of expression. FASEB J 1992; 6: 3290-9.
21. Pellerin S, Lafeuillade B, Chambaz M, Feige JJ. Distinct effects of thrombospondin-1 and CISP/thrombospondin-2 on adrenocortical cell spreading. Mol Cell Endocrinol 1994; 106: 181-6.
22. Chen H, Sottile J, O'Rourke KM, Dixit VM, Mosher DF. Properties of recombinant mouse thrombospondin 2 expressed in Spohoptera cells. J Biol Chem 1994; 269: 32226-32.
23. Silverstein RL, Leung LLK, Harpel PC, Nachman RL. Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J Clin Invest 1984; 74: 1625-33.
24. Lamszus K, Joseph A, Jin L, Yao Y, Chowdury S, Fuchs A, Polverini PJ, Goldberg ID, Rosen EM. Scatter factor binds to thrombospondin and other extracellular matrix components. Am J Pathol 1996; 149: 805-19.
25. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin. J Biol Chem 1995; 270: 7304-10.
26. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996; 271: 21-4.
27. Godyna S, Liau G, Stefansson S, Argraves WS. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 1995; 129: 1403-10.
28. 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. J Biol Chem 1995; 270: 9543-9.
29. Gartner TK. Endogenous platelet lectin and thrombospondin function. Semin Thromb Hemostas 1987; 13: 281-9.
30. 2+-mediated association glycoprotein G (thrombin-sensitive protein, thrombospondin) with human platelets. J Biol Chem 1980; 255: 11629-32.
31. George JN, Lyons RM, Morgan RK. Membrane changes associated with platelet activation. Exposure of actin on the platelet surface after thrombin-induced secretion. J Clin Invest 1980; 66: 1-9.
32. Hourdillé P, Hasitz M, Belloc F, Nurden AT. Immunocytochemical study of the binding of fibrinogen and thrombospondin to ADP- and thrombin-stimulated human platelets. Blood 1985; 65: 912-20.
33. Asch AS, Leung LLK, Policy MJ, Nachman RL. Platelet membrane topography: colocalization of thrombospondin and fibrinogen with the glycoprotein IIb-IIIa complex. Blood 1985; 66: 926-34.
34. Aiken ML, Ginsberg MH, Plow EF. Mechanisms of expression of thrombospondin on the platelet surface. Semin Thromb Hemost 1987; 13: 307-16.
35. Boukerche H. McGregor JL. Characterization of an antithrombospondin monoclonal antibody (P8) that inhibits human blood platelet function. Normal binding of P8 to thrombin-activated Glanzmann thrombasthenic platelets. Eur J Biochem 1988; 171: 383-92.
36. Legrand C, Dubernard V, Kieffer N, Nurden AT. Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem 1988; 171: 393-9.
37. Dubernard V, Legrand C. Characterization of the binding of thrombospondin to human platelets and its association with the platelet cytoskeleton. J Lab Clin Med 1991; 118: 446-57.
38. Watkins SC, Raso V, Slayter HS. Immunoelectron-microscopic studies of human platelet thrombospondin, von Willebrand factor, and fibrinogen redistribution during clot formation. Histochem J 1990; 22: 507-18.
39. Heilmann E, Hourdillé P, Pruvost A, Paponneau A, Nurden AT. Thrombin-induced platelet aggregates have a dynamic structure. Time-dependent redistribution of glycoprotein IIb-IIIa complexes and secreted adhesive proteins. Arterioscler Thromb 1991; 11: 704-18.
40. Leung LLK. Role of thrombospondin in platelet aggregation. J Clin Invest 1984; 74: 1764-72.
41. Gartner TK, Walz DA, Aiken M, Starr-Spires L, Ogilvie ML. Antibodies against a 23 kDa heparin binding fragment of thrombospondin inhibit platelet aggregation. Biochem Biophys Res Commun 1984; 124: 290-5.
42. Dixit VM, Haverstick DM, O'Rourke KM, Hennessy SW, Grant GA, Santoro SA, Frazier WA. A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci USA 1985; 82: 3472-6.
43. Kao KJ, Shaut DM, Klein PA. Functional involvement of thrombospondin in platelet aggregation induced by low versus high concentrations of thrombin. Thromb Haemostas 1986; 55: 136-42.
44. Tuszynski GP, Rothman VL, Murphy A, Siegler K, Knudsen KA. Thrombospondin promotes platelet aggregation. Blood 1988; 72: 109-15.
45. Legrand C, Morandi V, Mendelovitz S, Shaked H, Hartman JR. Panel A. Selective inhibition of platelet macroaggregate formation by a recombinant heparin-binding domain of human thrombospondin. Arterioscler Thromb 1994; 14: 1784-91.
46. Legrand C, Thibert V, Dubernard V, Bégault B, Lawler J. Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. Blood 1992; 79: 1995-2003.
47. Rabhi-Sabile S, Pidard D, Lawler J, Renesto P, Chignard M, Legrand C. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett 1996; 386: 82-6.
48. Tuszynski GP, Rothman VL, Deutch AH, Hamilton BK, Eyal J. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin properdin, and malarial proteins. J Cell Biol 1992; 116: 209-17.
49. Rabhi-Sabile S, Thibert V, Legrand C. Thrombospondin peptides inhibit the secretion-dependent phase of platelet aggregation. Blood Coag Fibrinol 1996; 7: 237-40.
50. Tuszynski GP, Kowalska MA. Thrombospondin-induced adhesion of human platelets. J Clin Invest 1991; 87: 1387-94.
51. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol 1994; 6: 695-704.
52. Huang M-M, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci USA 1992; 88: 7844-8.
53. Asch AS, Barnwell A, Silverstein RL, Nachman RL. Isolation of the thrombospondin receptor. J Clin Invest 1987; 79: 1054-61.
54. McGregor JL, Catimel B, Parmentier S, Clezardin P, Dechavanne M, Leung LLK. Rapid purification and partial characterization of human platelet glycorprotein IIIb. J Biol Chem 1989; 264: 501-6.
55. Kieffer N, Nurden AT, Hasitz M, Titeux M, Breton-Gorius J. Identification of platelet membrane thrombospondin binding molecules using an anti-thrombospondin antibody. Biochim Biophys Acta 1988; 967: 408-15.
56. Beiso P, Pidard D, Fournier D, Dubernard V, Legrand C. Studies on the interaction of platelet glycoprotein IIb-IIIa and glycoprotein IV with fibrinogen and thrombospondin: a new immunochemical approach. Biochim Biophys Acta 1990; 1033: 7-12.
57. Kowalska MA, Tuszynski GP. Interaction of thrombospondin with platelet glycoproteins GPIa-IIa and GPIIb-IIIa. Biochem J 1993; 295: 725-30.
58. Plow EF, McEver RP, Coller BS, Woods VL, Marguerie GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724-7.
59. Legrand C, Pidard D, Beiso P, Tenza D, Edelman L. Interaction of a monoclonal antibody to glycoprotein IV (CD36) with human platelets and its effect on platelet aggregation. Platelets 1991; 2: 99-105.
60. Kehrel B, Kronenberg A, Schwippert B, Niesing-Bresch D, Niehues U, Tschöpe D, van de Loo J, Clemetson KJ. Thrombospondin binds normally to glycoprotein IIIb deficient platelets. Biochem Biophys Res Commun 1991; 179: 985-91.
61. Tandon NN, Ockenhouse CF, Greco NJ, Jamieson GA. Adhesive functions of platelets lacking glycoprotein IV (CD36). Blood 1991; 78: 2809-13.
62. Brown E, Hooper L, Ho T, Gresham H. Integrin-associated protein: a 50-kDa plasma membrane antigen physically and functionally associated with integrins. J Cell Biol 1990; 111: 2785-94.
63. Dorahy DJ, Thorne RF, Fecondo JV, Burns GF. Stimulation of platelet activation and aggregation by a carboxy-terminal peptide from thrombospondin binding to the integrin-associated protein receptor. J Biol Chem 1997; 272: 1323-30.
64. Fukimoto T, Fujimura K, Noda M, Takafuta T, Shimomura T, Kuramoto A. 50-kDa integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets. Blood 1995; 86: 2174-82.
65. Wight TN, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. J Hystochem Cytochem 1985; 33: 295-302.
66. Arbeille BB, Fauvel-Lafeve FMJ, Lemesle MB, Tenza D, Legrand YJ. Thrombospondin: a component of microfibrils in various tissues. J Hystochem Cytochem 1991; 39: 1367-75.
67. Lahav J. Thrombospondin inhibits adhesion of platelets to glass and protein-covered substrata. Blood 1988; 71: 1096-9.
68. Agbanyo FR, Sixma JJ, de Groot PG, Languino LR, Plow EF. Thrombospondin-platelet interactions. Role of divalent cations, wall shear rate, and platelet membrane glycoproteins. J Clin Invest 1993; 92: 288-96.
69. Galvin NJ, Vance PM, Dixit VM, Fink B, Frazier WA. Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J Cell Biol 1987; 104: 1413-22.
70. Mumby SM, Raugi GJ, Bornstein P. Interaction of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J Cell Biol 1984; 98: 646-52.
71. Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ, van de Loo J. Deficiency of intact thrombospondin and membrane glycoprotein la in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988; 71: 1074-8.
72. Gerrard JM, Phillips DR, Rao GHR, Plow EF, Walz DA, Ross R, Harker LA, White JG. Biochemical studies of two patients with the gray platelet syndrome. J Clin Invest 1980; 66: 102-9.
73. Nurden AT, Kunicki TJ, Dupuis D, Soria C, Caen JP. Specific-protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood 1982; 59: 709-18.
74. Srivastava PC, Fowling MJ, Nokes TJC, Patrick AD, Dawes J, Hardisty RM. Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin. Br J Haematol 1987; 65: 441-6.
75. Mori K, Suzuki S, Sugai K. Electron microscopic and functional studies on platelets in gray platelet syndrome. Tohoku J Exp Med 1984; 143: 261-87.
76. Levy-Toledano S, Caen JP, Breton-Gorius J, Rendu F, Cywiner-Golenzer C, Dupuy E, Legrand Y, Maclouf J. Gray platelet syndrome: α-granule deficiency. J Lab Clin Med 1981; 98: 831-48.
77. Sloand E, Kenney DM, Chao FC, Lawler J, Tullis JL. Platelet antithrombin defect in malignancy: platelet protein alterations. Blood 1987; 69: 479-85.
78. Booth WJ, Berndt MC, Castaldi PA. An altered platelet granule glycoprotein in patients with essential thrombocythemia. J Clin Invest 1984; 73: 291-7.
79. Lawler J, Cohen AM, Chao FC, Moriarty DJ. Thrombospondin in essential thrombocythemia. Blood 1986; 67: 555-8.
80. Legrand C, Bellucci S, Disdier M, Edelman L, Tobelem G. Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: effect of α-interferon treatment. Am J Hematol 1991; 38: 307-13.
81. Lane DA, Ireland H, Wolff S, Ranasinghe E, Dawes J. Detection of enhanced in vivo platelet α-granule release in different patient groups. Comparison of β-thromboglobulin, platelet factor 4 and thrombospondin assays. Thromb Haemostas 1984; 52: 183-7.
82. Trzeciak M-C, McGregor J, Renaux J-L, Ville D, Berruyer M, Dawes J, Dechavanne M. Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. Thromb Res 1985; 40: 121-8.
83. Ffrench P, McGregor JL, Berruyer M, Belleville J, Touboul P, Dawes J, Dechavanne M. Comparative evaluation of plasma thrombospondin β-thromboglobulin and platelet factor 4 in acute myocardial infarction. Thromb Res 1985; 39: 619-24.
84. McCrohan MB, Huang SW, Sleasman JW, Klein PA, Kao KJ. Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis. Thromb Haemostas 1987; 58: 850-2.
85. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J. Thrombospondin levels in patients with malignancy. Thromb Haemostas 1992; 67: 607-11.
86. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR, Tuszynski GP. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 1994; 73: 2853-8.
87. Dawes J, Clemetson KJ, Gogstad GO, McGregor J, Clezardin P, Prowse CV, Pepper DS. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, β-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb Res 1983; 29: 569-81.
88. Dawes J, Pratt DA, Dewar MS, Preston FE. Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb Haemostas 1988; 59: 273-6.
89. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-8.
90. Legrand C, Woimant F, Haguenau M, Caen J. Platelet surface glycoprotein changes in patients with cerebral ischemia. Nouv Rev Fr Hematol 1991; 33: 497-500.
91. Tschoepe D, Schultheib HP, Kolarov P, Schwippert B, Dannehl K, Volksw D, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
92. Clezardin P, Serre C-M, Trzeciak M-C, Drouin J, Delmas PD. Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteocarcoma cell interaction. Cancer Res 1991; 51: 2621-7.
93. Katagiri Y, Hayashi Y, Baba I, Suzuki H, Tanoue K, Yamazaki H. Characterization of platelet aggregation induced by the human melanoma cell line HMV-I: roles of heparin. plasma adhesive proteins. and tumor cell membrane proteins. Cancer Res 1991; 51: 1286-93.
94. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 1987; 47: 4130-3.
95. Incardona F, Lewalle JM, Morandi V, Lambert S, Legrand Y, Foidart JM, Legrand C. Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res 1995; 55: 166-73.
96. Christopoulos C, Mattock C. Platelet satellitism and α granule proteins. J Clin Pathol 1991; 44: 788-9.
97. Silverstein RL, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelel-monocyte and platelet U937 cell adhesion. J Clin Invest 1989; 84: 546-52.
98. Schwartz BS. Monocyte synthesis of thrombospondin. The role of platelets. J Biol Chem 1989; 264: 7512-7.
99. Mansfield PJ, Suchard SJ. Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes. J Immunol 1994; 153: 4219-29.
100. Huber AR, Ellis S, Johnson KJ, Dixit VM, Varani J. Monocyte diapedesis through an in vitro vessel wall construct: inhibition with monoclonal antibodies to thrombospondin. J Leuk Biol 1992; 52: 524-8.
101. Kreis C, La Fleur M, Ménard C, Paquin R, Beaulieu AD. Thrombospondin and fibronectin are synthetized by neutrophils in human inflammatory joint disease and in a rabbit model of in vivo neutrophil activation. J Immunol 1989; 143: 1961-68.
102. Suchard SJ. Interaction of human neutrophils and HL-60 cells wih the extracellular matrix. Blood Cells 1993; 19: 197-223.
103. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992; 90: 1513-22.
104. Raugi GJ, Olerud JE, Gown AM. Thrombospondin in early human wound tissue. J Invest Dermatol 1987; 89: 551-4.
105. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J Histochem Cytochem 1993; 41: 1467-77.
106. DiPietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM, Polverini PJ. Thrombospondin 1 synthesis and function in wound repair. Am J Pathol 1996; 148: 1851-60.
107. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
108. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor-suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-8.
109. Taraboletti G, Roberts D, Liotta LA, Giavazzi R, Platelet thromhospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990; 111: 765-72.
110. Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 5026-30.
111. Tolsma SA, Volpert OG, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993; 122: 497-511.
112. Vogel T, Guo N-h, Krutsch HC, Blake DA, Hartman J, Mendelovitz S, Panet A, Roberts DD. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993; 53: 74-84.
113. Raychaudury A, Frazier WA, D'Amore PA. Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta. J Cell Sci 1994; 107: 39-46.
114. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-8.
115. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
116. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenicity. Proc Natl Acad Sci USA 1995; 92: 6788-92.
117. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin. Cancer Res 1996; 56: 5684-91.
118. Ben-Ezra D, Griffin BW, Maftzir G, Aharonov O. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Onhthalmol 1993; 34: 3601-8.
119. Nicosia R, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994; 124: 183-93.
120. Roberts DD, Sherwood JA, Spitalnik SL, Panton LJ, Howard RJ, Dixit VM, Frazier WA, Miller LH, Ginsburg V. Thrombospondin binds falciparum parasitized erythrocytes and may mediate cytoadherence. Nature 1985; 318: 64-66.
121. Rock EP, Roth EF, Rojas-Corona RR, Sherwood JA, Nagel RL, Howard RJ, Kaul DK. Thrombospondin mediates the cytoadherence of Plasmodium falciparum-infected red cells to vascular endothelium in shear flow conditions. Blood 1988: 71: 71-5.
122. Cooke BM, Berendt AR, Craig AG, MacGregor J, Newbold CI, Nash GB. Rolling and stationary cytoadhesion of red blood cells parasitized by Plasmodium falciparum: separate role for ICAM-1. CD36 and thrombospondin. Br J Haematol 1994; 87: 162-70.
123. Baruch DI, Gormely JA, Ma C, Howard RJ. Pasloske BL. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule I. Proc Natl Acad Sci USA 1996; 93: 3497-502.
124. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM. Thrombospondin from activated platelets promotes sickle erthyrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993; 81: 2137-43.
125. Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992; 80: 2634-42.
126. Joneckis C, Shock DD, Cunningham ML, Orringer EP, Parise LV. Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. Blood 1996; 87: 4862-70.
127. Hillery CA, Du MC, Montgomery RR, Scott JP. Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood 1996; 87: 4879-86.